About Tesa Reviews

What this site is

Tesa Reviews is an independent editorial project that publishes summaries of the peer-reviewed research literature on tesamorelin. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The "reviews" in our name means exactly one thing: a review of the published research — a digest of the trials, the meta-analysis, and the pharmacokinetic record. It does not mean product reviews, ratings, or a storefront. There is nothing here to buy, order, or price, and there is no clinic, pharmacy, or prescription service behind this site.

How we work

Every quantitative claim on this site is tied to a numbered citation, and every citation resolves to a real study with a DOI or PubMed identifier on the full reference list. We lead with what the trials actually measured and attribute it to the source. Where the evidence is precise — a 15.2% visceral-fat reduction in 412 HIV patients, an IGF-1 rise of 181 ug/L in 13 healthy men — we say so plainly. Where it is limited — no large general-population trial, reaccumulation on discontinuation, limited long-term oncologic data — we say that just as plainly.

We keep the technical depth and add a plain-English layer on top, so a curious non-scientist and a researcher can both read the same page. We describe findings; we do not recommend doses, and we do not present research-grade material as a medicine to self-administer.

What the name means

The editorial framing of "reviews" is a position this publisher occupies relative to the literature — a reviewer of published studies — not a claim about services we offer. Tesamorelin is FDA-approved only for HIV-associated lipodystrophy; all other uses are off-label, and we are careful to mark that boundary throughout. We are a reading of the evidence, kept honest about where the evidence stops.